Recovery and Then Individual Separation of Platinum, Palladium, and Rhodium from Spent Car Catalytic Converters Using Hydrometallurgical Technique followed by Successive Precipitation Methods by Ahmed M. Yousif

“…Recovery of PGMs (especially rhodium, platinum, and palladium) from different spent manufactured products (like catalytic converters) is considered as an important task as they are rarely found in nature, and they possess high economic value. …”
Get full text

Constructing SiO2‑Supported Atomically Dispersed Platinum Catalysts with Single-Atom and Atomic Cluster Dual Sites to Tame Hydrogenation Performance by Hao Xu, Dong Lin, Jie Shi, Zhengxing Lv, Xinshuo Zhao, Linge Ning, Jiao Xiao, Lin Cui, Jian Zhang, Juncong Yuan, Xiang Feng, Yong Qin, Jiankang Zhang

Get full text

Pembrolizumab plus Pemetrexed and Platinum in Metastatic Non-Squamous Non-Small Cell Lung Cancer: A Real-Life Study at a Portuguese Centre by Maria João Santos, Filipa Ferro, Andrea Machado, Ana Sofia Vilariça, Direndra Hasmucrai, Paula Alves

Subjects: Get full text

The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial by Elena Giudice, Tzu-Ting Huang, Jayakumar R. Nair, Grant Zurcher, Ann McCoy, Darryl Nousome, Marc R. Radke, Elizabeth M. Swisher, Stanley Lipkowitz, Kristen Ibanez, Duncan Donohue, Tyler Malys, Min-Jung Lee, Bernadette Redd, Elliot Levy, Shraddha Rastogi, Nahoko Sato, Jane B. Trepel, Jung-Min Lee

“…Here we report the activity of CHK1i in platinum-resistant high-grade serous ovarian carcinoma (HGSOC) with measurable and biopsiable disease (cohort 5), or without biopsiable disease (cohort 6). …”
Get full text

Platinum drugs upregulate CXCR4 and PD‐L1 expression via ROS‐dependent pathways, with implications for novel combined treatment in gastric cancer by Xiaoyu Kang, Lin Zhang, Shushang Liu, Fei Wang, Haiming Liu, Fenli Zhou, Fei Wu, Haohao Zhang, Daiming Fan, Yongzhan Nie, Zhangqian Chen

“…However, the impact of platinum drugs, such as cisplatin, on CXCR4 or PD‐L1 expression and the underlying mechanisms in gastric cancer (GC) remain unknown. …”
Get full text

New Boric Acid Derivative with Some of Its Complexes and Study the Biological and Anticancer Activity by Alaa Abdullah Majeed, Asmaa Mohammed Noori

Subjects: Get full text

Effect of Al2O3, MgO, and CuOx on the dissolution behavior of rhodium in the Na2O-SiO2 slags by Wiraseranee C., Yoshikawa T., Okabe T.H., Morita K.

Subjects: Get full text

Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR‐mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis by Shang‐Gin Wu, Chao‐Chi Ho, James Chih‐Hsin Yang, Shu‐Han Yu, Yen‐Feng Lin, Shu‐Chin Lin, Bin‐Chi Liao, Ching‐Yao Yang, Yen‐Ting Lin, Chong‐Jen Yu, Ya‐Ting Chuang, Wei‐Yu Liao, Kah Yi Yap, Weng Si Kou, Jin‐Yuan Shih

Get full text

Long noncoding RNA GDIL acts as a scaffold for CHAC1 and XRN2 to promote platinum resistance of colorectal cancer through inhibition of glutathione degradation by Xuan Deng, Lu Chang, Lingyu Tang, Haoqin Jiang, Xiao Xu, Xinju Zhang, Jian Chen, Liu Dong, Qianqian Xu, Ruoshui Cao, Jianbin Xiang, Ming Guan

“…Abstract Acquired resistance poses a significant obstacle to the effectiveness of platinum-based treatment for cancers. As the most abundant antioxidant, glutathione (GSH) enables cancer cell survival and chemoresistance, by scavenging excessive reactive oxygen species (ROS) induced by platinum. …”
Get full text

Creep rupture properties of bare and coated polycrystalline nickel-based superalloy Rene®80 by Barjesteh M.M., Abbasi S.M., Zangeneh-Madar K., Shirvani K.

Subjects: Get full text

Efficacy and Safety of Low-Dose Lenvatinib and Toripalimab in Patients With Recurrent Platinum-Resistant Ovarian Cancer: Study Protocol of a Multicenter, Open-Label, Single-Arm, Phase II Clinical Trial by Su H, Shang X, Liu H, Wang Y, Yu Y, Xu Y, Jiang K, Feng F

Subjects: Get full text

Novel platinum nanoclusters (Pt NCs) induce mitochondrial apoptosis and damaging autophagy for the treatment of osteosarcoma—from the perspective of P53 mutation status in different cell lines by Jialin Wang, Haodi Yue, Xin Huang, Hongjian Liu, Mengjun Zhang

“…Abstract This study aimed to investigate the anticancer efficacy and underlying mechanism of novel platinum nanoclusters (Pt NCs) in osteosarcoma cell lines exhibiting distinct P53 expression profiles, namely MG-63 (P53−) and U2-OS (P53+). …”
Get full text

Investigation of the optimal platinum-based regimen in the postoperative adjuvant chemotherapy setting for early-stage resected non-small lung cancer: a Bayesian network meta-analysis by Li Zhang, Wen-Feng Fang, Yi Lv, Lan-Lan Pang, Jia-Di Gan, Yi-Hua Huang, Jun Liao, Wael Abdullah-Sultan Ali

“…Objective This study aimed to compare the efficacy and safety of different platinum adjuvant chemotherapy regimens for early-stage resected non-small-cell lung cancer (NSCLC).Design Systematic review with network meta-analysis of randomised trials.Data sources PubMed, EMBASE, The Cochrane Library, Web of Science and Scopus Google Scholar were searched through 12 March 2021.Eligibility criteria Eligible randomised controlled trials (RCTs) comparing the postoperative platinum chemotherapy regimen with the observation-controlled group or comparing two platinum chemotherapy regimens head-to-head were included.Data extraction and synthesis The primary outcome was the efficacy of adjuvant chemotherapy regimens including relapse-free survival (RFS), overall survival (OS), 2-year, 3-year, 5-year RFS rate and OS rate. …”
Get full text

New directions processing of technogenic waste of the copper industry by B. R. Vokhidov, A. S. Khasanov, B. M. Nemenenok, G. F. Mamaraimov

Subjects: Get full text

Effectiveness and safety of PD-1/L1 inhibitors as first-line therapy for patients with advanced or metastatic urothelial carcinoma who are ineligible for platinum-based chemotherapy: a meta-analysis by Weiming Liang, Weiming Liang, Zhijing Wang, Zhilong Huang, Yanping Huang, Chunyan Li, Yiwen Liang, Miaoyan Huang, Duo Zhang, Chenchen Li

“…ObjectiveTo evaluate the efficacy and safety of programmed cell death protein 1 or its ligand (PD-1/L1) inhibitors as first-line therapy in advanced or metastatic urothelial carcinoma (mUC) who are ineligible for platinum-based chemotherapy.MethodA systematic search was conducted in four databases (Pubmed, Embase, Web of Science, and the Cochrane Library) to find articles that evaluate the effectiveness of first-line PD-1/L1 inhibitors for mUC, from the establishment of the databases to 22 November 2023. …”
Get full text

Studies of the Selective Removal of Micro-Quantities of Platinum(IV) Ions from Macro-Quantities of Model Solutions of Aluminium, Copper, Iron, Nickel and Zinc Chloride on Anion-Exchangers of Various Types by Z. Hubicki, G. Wójcik

“…Platinum has been widely applied as an industrial catalyst and consequently the recovery of noble metals from industrial wastes has become an economic issue. …”
Get full text

Outcomes for Dostarlimab and Real-World Treatments in Post-platinum Patients With Advanced/Recurrent Endometrial Cancer: The GARNET Trial Versus a US Electronic Health Record-Based External Control Arm by Scott Goulden, Qin Shen, Robert L. Coleman, Cara Mathews, Matthias Hunger, Ankit Pahwa, Rene Schade

“…**Background:** Patients with advanced or recurrent endometrial cancer (EC) have limited treatment options following platinum-based chemotherapy and poor prognosis. The single-arm, Phase I GARNET trial (NCT02715284) previously reported dostarlimab efficacy in mismatch repair–deficient/microsatellite instability–high advanced or recurrent EC. …”
Get full text

Poly-ADP ribose polymerase (PARP) inhibitor regimens for platinum-sensitive ovarian cancer in randomized, double-blind, phase III controlled trials: protocol for a systematic review and network meta-analysis by Xiaolian Peng, Jie Liu

“…IntroductionClinical trials have shown that PARP inhibitors are effective in treating patients with platinum-sensitive ovarian cancer. They have been indicated to improve progression-free survival or overall survival in patients with patients with platinum-sensitive ovarian cancer. …”
Get full text

Correction: Risk factors indicating immune-related adverse events with combination chemotherapy with immune checkpoint inhibitors and platinum agents in patients with non-small cell lung cancer: a multicenter retrospective study by Airi Fujimoto, Yoshimichi Koutake, Daisuke Hisamatsu, Noriko Ookubo, Yurika Yabuuchi, Go Kamimura, Tatsuo Kai, Aki Kozono, Takahiro Ootsu, Hiroto Suzuki, Keisuke Matsuo, Kimiko Kuwahara, Yoshita Oiwane, Yuko Nagata, Kenya Tanimoto, Eri Sato, Mei Suenaga, Tomohiro Uehara, Akira Ikari, Satoshi Endo, Yoichi Hiraki, Yosei Kawamata

Get full text

Evaluation of the Antitumor Effects of Platinum-Based [Pt(η1-C2H4-OR)(DMSO)(phen)]+ (R = Me, Et) Cationic Organometallic Complexes on Chemoresistant Pancreatic Cancer Cell Lines by Erika Stefàno, Luca Giulio Cossa, Federica De Castro, Erik De Luca, Viviana Vergaro, Giulia My, Gianluca Rovito, Danilo Migoni, Antonella Muscella, Santo Marsigliante, Michele Benedetti, Francesco Paolo Fanizzi

“…For the interesting cytotoxic activity observed on YAPC, further biological assays were performed, on this cancer cell line, to evaluate the apoptotic and antimetastatic properties of the considered platinum compounds (1 and 2). The cytotoxicity of 1 and 2 compounds appeared to be related to their intracellular accumulation, which was much faster than that of cisplatin. …”
Get full text